Jonas Bergh

Selected publications 2008-2012

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J.

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

J Clin Oncol. 2012 Jul 20;30(21):2601-8.

Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, Lindemann JP, Wiklund F, Henriksson R.

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

J Clin Oncol. 2012 Jun 1;30(16):1919-25.

Jonsson B, Bergh J.

Hurdles in anticancer drug development from a regulatory perspective.

Nat Rev Clin Oncol. 2012 Feb 21;9(4):236-43.

Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C.

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

J Clin Oncol. 2012 Mar 20;30(9):921-9.

Howell A, Bergh J

Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer.

J Clin Oncol. 2010 Oct 20;28(30):4548-50. Epub 2010 Sep 20

Koscielny S, Arriagada R, Adolfsson J, Fornander T, Bergh J

Impact of tumour size on axillary involvement and distant dissemination in breast cancer.

Br JCancer. 2009 Sep 15;101(6):902-7. Epub 2009 Aug 18

Wennmalm K, Ostman A, Bergh J

Stromal signature identifies basal breastcancers.

Nat Med. 2009 Mar;15(3):237-8; author reply 238

Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.

Nat Med. 2009 Jan;15(1):68-74. Epub 2009 Jan 4

Bergh J

Quo vadis with targeted drugs in the 21st century?

J Clin Oncol. 2009 Jan 1;27(1):2-5. Epub 2008 Dec 1

Lidgren M, Jönsson B, Rehnberg C, Willking N, Bergh J

Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.

Ann Oncol. 2008 Mar;19(3):487-95. Epub 2007 Dec 6

Content Editor: Arne Östman
Last modified by: Erika Rindsjö 2013-03-05